iPierian, Stem Cell Startup With Big Science & Big Bucks, Axes Group of Top Executives

San Francisco-based iPierian has undergone a major restructuring of its management team and strategic focus since its formation in 2009 from a merger between iZumi Bio and Pierian. iPierian, a leader in the development of ALS patient-derived iPS cell technology, has decided to trim its scope of scientific programs in an effort to reduce its cash burn rate and position itself for acquisition.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail